Cassava Sciences Inc (SAVA)

[phil713]

“For years, opioid drugs were heavily marketed, inappropriately prescribed and lightly regulated, creating ideal conditions for an opioid epidemic,” said Remi Barbier, President & CEO. “Considering the staggering consequences, and the need to balance potential solutions with appropriate access to pain meds, FDA’s resistance to REMOXY remains a bit of a mystery. We hope for clarity and answers when we meet with FDA on January 31st to discuss this matter.”

I think the lead up to the 1/31 meeting we will see an increase in PTIE price $1.50-$2 before the meeting. Depending on the news, that $10 to $20 is not out of the question. I agree with your 20/80 odds, though.

https://ih.advfn.com/stock-market/NASDAQ/pain-therapeutics-PTIE/stock-news/79002246/pain-therapeutics-announces-two-new-peer-reviewed